Based in Zurich, Molecular Partners is developing a new class of drugs that can address the complexity of cancer. At Labiotech Refresh in Zurich, CEO Patrick Amstutz shared what he’s learned on the journey to take the company where it is today. After completing a PhD at ETH Zurich, Amstutz founded Molecular Partners with a […]
The post Taking a Drug to Market “Is a Marathon, Not a Sprint” appeared first on Labiotech.eu.
Original Article: Taking a Drug to Market “Is a Marathon, Not a Sprint”